Hormone replacement therapy and incidence of acute myocardial infarction: A population-based nested case-control study

Circulation

Volumn 101, Issue 22, 2000, Pages 2572-2578

  Varas Lorenzo, Cristina ^a,c   García Rodríguez, Luis A ^b   Perez Gutthann, Susanne ^a   Duque Oliart, Alberto ^a  

^a Unidad de Health Outcomes Research   (Spain)

^b Department of Pharmacoepidemiology   (Spain)

^c Global Epidemiology   (Spain)

Author keywords

Epidemiology; Hormones; Myocardial infarction; Prevention; Women

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ESTRADIOL; ESTROGEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0343527288     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.22.2572     Document Type: Article

References (28)

1. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids. 1990;55:330-352.
2. Barrett-Connor E. Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 1997; 95:252-264.
3. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system: review. N Engl J Med. 1999;340:1801-1811.
4. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Annu Rev Public Health. 1998;19:55-72.
5. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, et al. Hormone replacement therapy and risk of venous thromboembolism: a population based case-control study. BMJ. 1997;314:796-800.
6. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419-425.
7. Perry J, ed. OXMIS Problem Codes for Primary Medical Care. Oxford, UK: Oxmis Publications; 1978.
8. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302:766-768.
9. Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerised data resource in the United Kingdom. Pharmacoepidemiol Drug Safety. 1992;1:347-349.
10. World Health Organization Regional Office for Europe. Myocardial Infarction Community Registers. Copenhagen, Denmark: WHO; Public Health in Europe No. 5; 1976.
11. Gillum RF, Fortmann SP, Prineas RJ, et al. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J. 1984;108:150-158.
12. Walker AM. Observation, and Inference. Newton Lower Falls, Mass: Epidemiology Resources Inc; 1991.
13. Kahn HA, Sempos CHT. Statistical Methods in Epidemiology. New York, NY: Oxford University Press; 1989.
14. Rothman KJ, Greeland S. Modern Epidemiology. Philadelphia, Pa: Lippincott-Raven Publishers; 1998.
15. SAS System for Personal Computers, Release 6.08. Cary, NC: SAS Institute Inc; 1992.
16. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-1775.
17. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
18. Donahue RP, Barrett-Connor E, Orchard TJ, et al. Endogenous insulin and sex hormones in atherosclerosis and coronary heart disease. Arteriosclerosis. 1988;8:544-548.
19. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1998;158:617-621. Review.
20. Kaplan RC, Heckbert SR, Weiss NS, et al. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care. 1998; 21:1117-1121.
21. Lawrenson RA, Leydon GM, Newson RB, et al. Coronary heart disease in women with diabetes: positive association with past hysterectomy and possible benefits of hormone replacement therapy. Diabetes Care. 1999; 22:856. Letter.
22. Dubuisson JT, Wagenknecht LE, D'Agostino RB Jr, et al. Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes. Diabetes Care. 1998;21:1790-1796.
23. Posthuma WF, Westendorp RG, Vanderbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994;308:1268-1269.
24. Sturgeon SR, Schairer C, Brinton LA, et al. Evidence of a healthy estrogen user survivor effect. Epidemiology. 1995;6:227-231.
25. Matthews KA, Kuller LH, Wing RR, et al. Prior use of estrogen replacement therapy: are users healthier than nonusers? Am J Epidemiol. 1996;143:971-978.
26. Grodstein F. Invited commentary: can selection bias explain the cardiovascular benefits of estrogen replacement therapy? Am J Epidemiol. 1996;143:979-982.
27. Lancaster T, Surman G, Lawrence M, et al. Hormone replacement therapy: characteristics of users and non-users in a British general practice cohort identified through computerised prescribing records. J Epidemiol Community Health. 1995;49:389-394.
28. Grodstein F, Stampfer MJ. Estrogen for women at varying risk of coronary disease. Maturitas. 1998;30:19-26.